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TDP43 proteinopathy is associated with aberrant DNA methylation in human amyotrophic lateral
sclerosis
Background: Amyotrophic lateral sclerosis (ALS) is a
fatal neurodegenerative disease characterized by motor
neurone (MN) degeneration and death. ALS can be
sporadic (sALS) or familial, with a number of associ-
ated gene mutations, including C9orf72 (C9ALS). DNA
methylation is an epigenetic mechanism whereby a
methyl group is attached to a cytosine (5mC), result-
ing in gene expression repression. 5mC can be further
oxidized to 5-hydroxymethylcytosine (5hmC). DNA
methylation has been studied in other neurodegenera-
tive diseases, but little work has been conducted in
ALS. Aims: To assess differences in DNA methylation
in individuals with ALS and the relationship between
DNA methylation and TDP43 pathology. Methods:
Post mortem tissue from controls, sALS cases and
C9ALS cases were assessed by immunohistochemistry
for 5mC and 5hmC in spinal cord, motor cortex and
prefrontal cortex. LMNs were extracted from a subset
of cases using laser capture microdissection. DNA from
these underwent analysis using the MethylationEPIC
array to determine which molecular processes were
most affected. Results: There were higher levels of
5mC and 5hmC in sALS and C9ALS in the residual
lower motor neurones (LMNs) of the spinal cord.
Importantly, in LMNs with TDP43 pathology there
was less nuclear 5mC and 5hmC compared to the
majority of residual LMNs that lacked TDP43 pathol-
ogy. Enrichment analysis of the array data suggested
RNA metabolism was particularly affected. Conclu-
sions: DNA methylation is a contributory factor in
ALS LMN pathology. This is not so for glia or neocor-
tical neurones.




Amyotrophic lateral sclerosis (ALS) is the most com-
mon motor neurone disease. It is characterized by
progressive loss of motor function brought on by
degeneration and death of motor neurones (MNs)
and was first described in 1869 [1]. Degeneration is
seen in both upper motor neurones (UMN) and lower
motor neurones (LMN), leading to muscle weakness,
spasticity and atrophy, with death typically occurring
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within 3 years after disease onset. The incidence of
ALS is 1.5–2 per 100 000 people, per year, with a
prevalence of 5–7 per 100 000 people worldwide [2].
The causes of ALS are not completely elucidated.
Risk factors include having an immediate family
member diagnosed with the disease, a lifestyle with
vigorous prolonged exercise [3] and advanced age
[4]. Pathologically, ALS is characterized by lower
motor neurone loss, with a subset of residual motor
neurones showing so-called TDP43 proteinopathy:
There is a loss of TAR DNA-binding protein 43 kDa
(TDP43) from its normal location in the nucleus,
with the concomitant formation of cytoplasmic aggre-
gates of ubiquitylated, phosphorylated, cleaved TDP43
in the cytoplasm [5,6].
ALS is classified as either familial ALS (fALS) or spo-
radic ALS (sALS): fALS is defined as having a family
history of ALS, potentially with a known associated
gene mutation. sALS refers to cases with no known
family history of the disease. Sporadic cases account for
the majority of ALS, (90–95%). fALS makes up 5–10%
of diagnoses, defined as specific associated genetic dom-
inant inheritance of a mutated gene or having first- or
second-degree family member with the disease,
although some nonautosomal dominant cases have
been reported [7].
Mutations in the chromosome 9 open-reading frame
(C9orf72) gene are found in 37% of fALS cases and 7%
of sALS cases, making it the most commonly mutated
gene in ALS [8]. TDP43 is coded for by the TARDBP
gene [9]. Mutations in the TARDBP gene account for
approximately 1% of sALS cases and 4% of fALS cases
[10]. TDP43 proteinopathy as described earlier is seen
in almost all cases of sALS as well as most genetic
forms (including C9ALS, and ALS due to TARDBP
mutations). TDP43 has a number of roles in normal
cellular function (see below) and has been posited to
have many pathological roles in ALS, including
changes in protein stability and degradation, impaired
cytoskeletal function and altered homeostasis of DNA-
and RNA-binding proteins [11].
TDP43 is mainly localized to the nucleus, but also
shuttles to and from the cytoplasm. Within the
nucleus, TDP43 regulates splicing of both noncoding
and protein-coding genes involved in neuronal survival
[12] and mitochondrial homeostasis maintenance by
regulating mitochondrial transcript processing [13]. In
the cytoplasm, TDP43 is also involved in transcription
regulation, RNA transport and stress granule formation
in response to cellular stress [14].
TDP43 is can also bind DNA and was first identified
as a co-factor that binds to a regulatory element in the
long terminal repeat of the human immunodeficiency
virus type 1 (HIV-1), resulting in in vitro transcription
being repressed from this element [9].
Aside from the possible role of TDP43 in DNA process-
ing as described above, there are other reasons why
study of DNA pathology in ALS may be of interest. Here,
we focus on DNA methylation. DNA damage in this ser-
ies of ALS brains has been reported elsewhere [15].
Epigenetics: DNA methylation
Epigenetic changes are defined as stable alterations that
are made to either DNA or histone proteins that alter
gene expression, but do not affect the base sequence.
Epigenetic mechanisms are involved in gene expression
regulation and are required for specific cell-type differ-
entiation [16]. DNA methylation is the process of
attaching a methyl group to a DNA base – usually a
cytosine that is followed by a guanine, so-called CpG
sites. This can result in gene silencing if the methyla-
tion event prevents the binding of transcription factors
to a gene promoter by changing the chromatin struc-
ture. DNA methylation has also been shown to be
involved in promoting genomic stability [17].
DNA methyltransferases (DNMTs) are responsible for
the attachment of methyl groups to cytosine nucleo-
tides in DNA and have two classes: De novo DNMTs are
able to newly methylate cytosines, setting up DNA
methylation patterns (DNMT3a and DNMT3b), whereas
maintenance DNMTs maintain these DNA methylation
patterns (DNMT1).
Cytosine methylation results in the formation of 5-
methylcytosine (5mC). This can be oxidized by ten-ele-
ven translocation (TET) enzymes to 5-hydroxymethyl-
cytosine (5hmC). Further oxidation results in further
demethylation into 5-formylcytosine (5fC) and 5-car-
boxylcytosine (5caC) [18]. Terminal deoxynucleotidyl
transferase (TdT) or thymine DNA glycosylase (TDG)
convert 5fC and 5caC back to unmethylated cytosine
by base excision repair [19].
The presence of 5mC is implicated in gene expression
repression, synaptic plasticity, gene imprinting, chro-
matin structure maintenance and X-chromosome inac-
tivation. It is enriched in genes encoding proteins with
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function in neurones and other nervous system cells
[20]. 5hmC levels have been shown to be generally
present at 10% of the levels of 5mC in the genome
[21], but with higher levels present in the CNS [22].
5fC and 5caC levels are even less abundant in the gen-
ome than both 5mC and 5hmC [18].
DNA methylation in ALS
There are good reasons to suppose that DNA methyla-
tion levels are altered in ALS. First, age is one of the
most important risk factors for ALS [4]. This raises the
question of which age-related changes cause suscepti-
bility for ALS. It is well established that DNA methyla-
tion alters with age. First, the so-called ‘epigenetic drift’
describes the tendency towards less consistent methyla-
tion with age, with an overall net reduction in methy-
lation across the genome [23]. Second, epigenetic age
estimators, referred to as ‘epigenetic clocks’, indicate
how biologically aged a specific tissue or blood is in
comparison to the chronological age of an individual
based on the pattern of gene methylation seen. Hor-
vath’s clock is the most well-known of the epigenetic
clocks [24]. Such epigenetic age estimators use sets of
CpGs to estimate the age of a tissue. Epigenetic clock
algorithms have been used to study age-related neu-
rodegenerative conditions, including Alzheimer’s dis-
ease (AD), dementia, Huntington’s disease (HD) and
Parkinson’s disease [25], with findings suggesting an
accelerated epigenetic age in those with neurodegener-
ative conditions compared to those who were neurolog-
ically healthy.
DNA methylation changes have been observed for
neurodegenerative diseases using other technologies as
well. Thus, for example altered methylation status has
been demonstrated variously by immunohistochemistry
for 5mC and 5hmC, gas chromatography/mass spec-
trometry, and the Illumina 450k array platform in Alz-
heimer’s disease, dementia with Lewy bodies,
Huntington disease and frontotemporal lobar degenera-
tion [26-30].
The first study to investigate the role DNA methyla-
tion played in ALS was an epigenome wide association
study (EWAS) [31]. Frontal cortex from ten sALS
patients and ten controls underwent DNA methylation
analysis using Affymetrix GeneChip Human Tiling 2.0R
arrays. A number of genes were found to be differen-
tially methylated, with pathway analysis showing
altered DNA methylation in genes involved in calcium
homeostasis, oxidative stress and neurotransmission.
A second study to use EWAS in ALS, has shown glo-
bal increases in 5mC and 5hmC levels in post mortem
sALS spinal cord, but not in blood [32]. This suggests
that the DNA methylation profiles in the CNS differ
from those of blood. This highlights that blood
biomarkers may not be a good indicator of crucial DNA
methylation changes in ALS and illustrates cell- and
tissue-specificity of DNA methylation patterns.
A key issue is the ability to assess individual cell
types: Methylation is a mechanism that is key to cellu-
lar differentiation, and simultaneous analyses of differ-
ent tissue types can find different methylation patterns
in any given disease. Thus, each cell type within the
CNS would be expected to have different DNA methyla-
tion patterns [16]. Furthermore, ALS is characterized
by a loss of neurones and myelin with a concomitant
astrogliosis and microgliosis [33]. Therefore, differing
methylation profiles will be seen between control and
disease tissue purely because of the shift in cellular
composition. It is therefore necessary to determine each
cell type’s specific methylation pattern in relation to
disease.
In summary, the literature to date reveals: First, age
is a key risk factor for ALS, raising the question as to
what age-related changes are relevant to the develop-
ment of disease. Second, DNA methylation profiles alter
with age and a number of other neurodegenerative dis-
eases. Third, the DNA methylation pattern seen can be
both cell- and tissue-specific. Finally, while RNA-based
pathology has been intensively researched with respect
to ALS, DNA-related pathology has been relatively
neglected. We have therefore addressed this in post
mortem CNS samples from individuals with sporadic
ALS and ALS due to C9orf72 mutations. Using
immunohistochemistry on post mortem CNS samples,
we have assessed levels of methylation and hydrox-
ymethylation in glia, lower motor neurones, upper
motor neurones and pyramidal cells of the prefrontal
cortex. Using Illumina EPIC gene chips, we have
assessed which biological processes are predominantly
affected in lower motor neurones.
Materials and Methods
Formalin-fixed, paraffin-embedded (FFPE) human post
mortem spinal cord, motor cortex and anterior frontal
© 2020 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
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cortex taken from the middle frontal gyrus was
obtained from the Sheffield Brain Tissue Bank (SBTB).
For this study, sections from were used from three
groups: controls, sporadic ALS (sALS) and ALS caused
by C9orf72 mutations (C9ALS). Groups were age- and
sex-matched, as far as was possible. Ethical approval
for this study has been granted by the Management
Committee of SBTB, which in turn has ethical approval
to provide tissue for research under the provision to act
as a Research Tissue Bank as approved by the Scotland
A Research Ethics Committee (ref. 08/MRE00/103).
Immunohistochemistry
IHC was carried out for TDP43, 5mC and 5hmC. Sections
were subjected to IHC using the standard ABC technique
(Leica, UK). Positive controls were used to assess the effi-
ciency of staining. Either negative controls or IgG isotype
controls were conducted, with the primary antibody step
omitted from one section in each IHC run. Antibody speci-
ficity checks were carried out for both 5mC and 5hmC to
ensure that any immunopositive staining observed was
specific: Preabsorption of the antibodies was carried out,
as well as DNase treatments.
Sections were first blocked for 30 min at room tem-
perature (RT), followed by primary antibody incubation
(see Table S1 for providers and conditions). The sec-
ondary antibody was applied for 30 min at RT, fol-
lowed by ABC incubation for 30 min at RT.
Immunopositive staining was visualized using DAB.
Cell counting
The immune-stained slides were digitized using the
Hamamatsu NanoZoomer XP, visualized by NDP.view2
digital pathology software (Hamamatsu Photonics,
Japan) and counted by the first author (CAM, Figure 1).
Prior to this, Cohen’s kappa coefficient [34] was used to
assess the reliability of this method of assessing nuclear
immune-positivity for neurons and glia: A series of 140
cells per assessment were classified by CAM and a quali-
fied diagnostic neuropathologist (JRH) revealing all
j ≥ 0.81 indicating a high level of reproducibility. Two
rounds of cell counting and assessment were performed.
First, in order to assess differences in methylation
between ALS and control cases, counts were made of
neuronal and glial nuclei that were positive and nega-
tive for 5hmC and 5hmC irrespective of TDP43 status.
A larger number of cells were counted for this analysis
as there was no requirement for visualization in adja-
cent slides. This was performed in the following struc-
tures (See Tables S2–S4 for demographics):
(1). Anterior horn, lateral corticospinal tract and dor-
sal column in the spinal cord (n = 10 controls, 10
sALS cases and 10 C9ALS);
(2). Neocortex and underlying white matter of the
motor cortex (n = 8 controls, 21 sALS cases and
12 C9ALS cases);
(3). Neocortex and underlying white matter of the mid-
dle frontal gyrus/anterior frontal cortex (n = 11
controls, 30 sALS cases and 12 C9ALS cases).
Second, in order to assess the effect of TDP43 pro-
teinopathy (nuclear loss of TDP43) on lower motor neu-
rones in ALS cases, sequential, adjacent sections of spinal
cord were immunostained for TDP43, 5mC and 5hmC.
The digitized whole-slide images were aligned such that the
same neurone nucleus could be simultaneously assessed
for either both TDP43 and 5mC or TDP43 and 5hmC (Fig-
ure S1). MN nuclei were graded to assess nuclear
immunopositive and immunonegative staining. A total of
200 cells were assessed for either 5mC and TDP43 or
5hmC and TDP43 in 20 ALS cases (10 sALS and 10
C9ALS cases, demographics as per Table S2) were assessed.
Statistical analysis was carried out using either SPSS
version 24 or 25. An inter-rater reliability test (Cohen’s
Kappa) was conducted to assess the reliability, validity
and reproducibility of cell counting. This calculation is a
chance-corrected version of the observed agreement. High
agreement between observers indicates diagnosis consen-
sus as well as consensus on the interchangeability and
reliability of the ratings. One-way ANOVA was also used
to assess any potential relationships between 5mC/5hmC
status in the MNs and TDP43 pathology. One-way
ANOVA was also used to test differences in the percentage
of cells that were immunopositive for 5mC and 5hmC
between the three groups (controls, sALS and C9ALS).
Intergroup comparisons are also presented as barcharts
with error bars indicating one standard deviation.
MethylationEPIC array
Formalin-fixed, paraffin-embedded human post mortem
spinal cord was obtained from the SBTB. For this study,
sections were from three groups: controls, sALS and
C9ALS, with n = 6 for each cohort (total n = 18,
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Table S5). 10 µm sections of tissue were mounted onto
uncharged slides, followed by dewaxing and rehydration.
Lower motor neurones (LMN) were visualized using tolu-
idine blue (0.01%), before being dehydrated, cleared in
xylene and air dried for 1hr. LMNs were extracted from
tissue using laser capture microdissection (LCM). The Arc-
turus VERITASTM LCM system (Applied Biosystems), in
conjunction with Arcturus Capsure Macro LCM Caps (Life
Technologies), was used with the following settings:
30 µm spot size, 70 mW laser power, 2500 µsec pulse,
one hit, 200 mV laser intensity and 0 msec delay.
Approximately 10 000 cells were collected per case on six
caps. DNA was extracted using the Zymo quick-DNATM
FFPE kit (Zymo Research), as per manufacturer’s protocol.
Bisulphite conversion was then performed using the Zymo
EZ DNA Methylation-Direct Kit (Zymo Research). A Nano-
Drop 1000 spectrophotometer (Thermoscientific) and
Agilent HS DNA chip were used to assess DNA quantity
and quality. DNA methylation was assessed using the
Illumina Infinium MethylationEPIC BeadChip and
imaged on an Illumina HiSeq 2500 scanner.
Bioconductor and the programming language R (version
3.5.0), using the RnBeads package in conjunction with a
GUI vignette, known as the RnBeads Data Juggler, were
used to analyse the BeadChip data [35,36]: IDAT files con-
taining the data collected from the scanned BeadChips
along with a.csv file containing case details were loaded
into Data Juggler. All analysis was sorted based on differen-
tially methylated promoters, with a = 0.05. This was then
further sorted by identifying which promoters were classed
as either hypomethylated or hypermethylated in ALS vs.
control. Gene ontology analysis was carried out as part of
the RnBeads analysis. GO terms were considered significant
at P < 0.01 following Benjamini–Hochberg correction.
Results
DNA methylation and hydroxymethylation is higher
in lower motor neurones (LMNs) affected by ALS
The relationship between ALS pathology and methylation
was explored by counting the overall percentage of LMNs in
Figure 1. Representation of grading system used for slide analysis in TDP43 and 5mC/5hmC sequential staining. Images taken at 980
magnification, scale bar represents 100 µm. (a) MN nucleus displaying 5hmC immunopositive staining, (b) MN nucleus displaying 5hmC
immunonegative staining, (c) MN nucleus displaying TDP43 immunopositive staining, (d) MN nucleus displaying TDP43
immunonegative staining, with TDP43-positive inclusion in cytoplasm (arrow), (e) MN nucleus displaying 5mC immunopositive staining,
(f) MN nucleus displaying 5mC immunonegative staining.
© 2020 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
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the anterior horn of spinal cord that were positive for 5mC
and 5hmC in controls and two ALS groups (sALS and
C9ALS). The percentage of LMN that were positive for 5mC
and 5hmC was significantly lower in controls
(76.3  7.1% for 5mC; 81.6  5.7% for 5hmC) than both
sALS (89.5  3.3%, P = 0.01 for 5mC; 90.4  3.8%,
P = 0.001 for 5hmC) and C9ALS (90.9  3.1%,
P = 0.003 for 5mC; 90.7  4.7%, P = 0.0007 for 5hmC,
Figure 2). No difference was observed between the two ALS
groups (sALS and C9ALS; P ≥ 0.53).
5mC and 5hmC levels in spinal cord glia do not
differ between controls and ALS
Counts of 5mC and 5hmC positive and negative glia
were similarly carried out in the anterior horn, lateral
corticospinal tract and dorsal column of the spinal
cord. In contrast to lower motor neurones, there were
no significant intergroup differences in the levels of
glial methylation and hydroxymethylation in any of
the regions investigated (P ≥ 0.05).
There is minimal difference in neuronal or glial 5mC or
5hmC inmotor cortex and anterior frontal cortex in ALS.
Having demonstrated altered methylation and
hydroxymethylation in the lower motor neurones (but
not glia) of the spinal cord, we next investigated
whether this would be observed in the forebrain. For
the motor cortex, there were no intergroup differences
in levels of methylation or hydroxymethylation for neu-
rones (P ≥ 0.22) or glia (P ≥ 0.17).
For the anterior frontal cortex (middle frontal gyrus),
only very minor changes were observed in neurones:
There was slightly greater 5mC labelling in sALS (mean
75.8%, SD 6.0%) than controls (mean 71.7%, SD 4.3%;
P = 0.04). There was slightly greater 5hmC labelling in
sALS (mean 76.3%, SD 5.2%) than C9ALS (mean 72.3%,
SD 3.4%; P = 0.02). Other intergroup comparisons for
5mC and 5hmC were nonsignificant (P ≥ 0.20). For the
anterior frontal cortex glia, there were no significant
intergroup differences for 5mC or 5hmC, (all P ≥ 0.24).
There is greater DNA methylation in lower motor
neurones than upper motor neurones.
Having demonstrated that residual spinal cord lower
motor neurones in ALS had greater levels of methylation
and hydroxymethylation than controls, but that there
were no such intergroup differences seen in the upper
motor neurones of the precentral gyrus or the neurones
of the anterior frontal cortex. We were thus interested to
know if forebrain and spinal cord neurones differed in
their levels of DNA methylation. There were higher levels
of DNA methylation and hydroxymethylation in the
spinal cord than in motor and anterior frontal cortices
(all P ≤ 2 9 1010) across the entire cohort (control,
sALS and C9ALS cases combined). This was also seen
when the analysis was restricted to cases from the con-
trol cohort alone (P ≤ 0.0003).
TDP43 pathology is associated with lower DNA
methylation and hydroxymethylation
Having demonstrated greater levels of methylation and
hydroxymethylation in the lower motor neurones in
sALS and C9ALS, we proceeded to study the effect of
TDP43 pathology on these cells in ALS: Individual
(a) (b)
Figure 2. Differences in global levels of 5mC and 5hmC in motor neurones of the anterior horn are present between control and disease
(mean, with error bars corresponding to one standard deviation). n = 10 for each group, total n = 30. (a) Significantly higher 5mC is
observed in sALS and C9ALS cases than controls (P = 0.0001 and 0.0002 respectively). No difference was observed between the two
diseased groups (P = 0.48). (b) Significantly higher 5mC is observed in sALS and C9ALS cases than controls (P = 0.0011 and 0.00072
respectively). No difference was observed between the two diseased groups (P = 0.88).
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lower motor neurone nuclei were identified in adjacent
sections and assessed for TDP43 (loss of labelling corre-
sponding to pathology). Each neurone was then found
on the adjacent section and assessed for either 5mC or
5hmC. In neurones with normal, TDP43-positive
nuclei, there were high levels (mean  SD) of 5mC and
5hmC (72.7%  15.5 of nuclei were positive for 5mC;
86.9%  6.0 positive for 5hmC). However, a signifi-
cantly lower percentage of MN nuclei displayed
immunopositivity for 5mC and 5hmC in pathological
neurones where nuclear TDP43 was absent
(27.7%37.9, P = 0.00002 for 5mC, and
50.7%  16.6, P < 0.00001 for 5hmC, Figure 3).
ALS has significantly differentially methylated
promoter regions
Having found differential methylation in lower motor
neurones in ALS, we next wished to gain some indica-
tion of which processes were most affected by this.
MNs were extracted from the anterior horn of human
post mortem cervical spinal cord by laser capture
microdissection and analysed by Illumina Infinium
MethylationEPIC BeadChip (n = 6 in each group, total
n = 18; data available at the University of Sheffield
online research data hub, https://orda.shef.ac.uk/, with
the access code 10.15131/shef.data.12058110).
First, this revealed that there was a greater number
of methylated sites in C9ALS cases (mean of 419 966
sites methylated, SD = 98 783) than controls (mean of
263 207 methylated sites, SD = 38 856; P = 0.011).
There was an intermediate number of methylated sites
in sALS cases (mean of 309 017 sites methylated,
SD = 57 157), that was not significantly different from
either the control or C9ALS groups.
Next, the analysis focussed more specifically on
methylation of known gene promoters – a subset of the
number of methylation sites assessed by the array. A
total of 732 gene promoters were identified as being
significantly differentially methylated in ALS compared
to controls at P ≤ 0.05): 402 promoters were hyperme-
thylated in ALS, and 330 were hypomethylated in
ALS. The degree of dysmethylation was more profound
in the hypermethylated promoters, with a mean
increase in methylation of 21.8% in ALS compared to
controls, with hypomethylated promoters showing a
mean decrease in methylation of 9.4% in ALS vs. con-
trols. Of the 732 promoters, 378 were identified as pro-
tein-coding according to the GeneCards database [37].
RNA metabolism dysregulation in ALS
Gene ontology (GO) analysis was conducted as part of the
RnBeads analysis in order to identify which biological pro-
cesses were most affected by dysmethylation of protein cod-
ing gene promoters in ALS. This was performed separately
for hypermethylated and hypomethylated protein-coding
gene promoters with processes considered significant at
P < 0.01 following Benjamini–Hochberg correction. A
number of pathways involved with neurodegeneration
were found. For hypermethylation, 30 GO terms were
enriched, many of which implicate RNA processing,
nucleic acid processing and RNA splicing. For hypomethy-
lated genes, only eight GO terms were enriched, the most
significant of which related to urea homeostasis (Table 1).
Discussion
We have performed an investigation into DNA methy-
lation in post mortem CNS tissues in amyotrophic
(a) (b)
Figure 3. 5mC and 5hmC loss from the nucleus of motor neurones is related to TDP43 motor neurone nuclear loss (mean, with error
bars corresponding to one standard deviation). (a) 5mC. High levels of methylation were present in motor neurone nuclei positive for
TDP43. However, a significantly lower percentage of motor neurone nuclei displayed immunopositivity for 5mC when nuclear TDP43
was lost, P = 0.00002. (b) 5hmC. High levels of methylation were present in motor neurone nuclei expressing TDP43. However, a
significantly lower percentage of motor neurone nuclei displayed immunopositivity for 5hmC when nuclear TDP43 was lost,
P < 0.00001.
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lateral sclerosis. Using immunohistochemistry, we
found that there were greater levels of methylation and
hydroxymethylation in the residual lower motor neu-
rones of both sporadic ALS and C9ALS compared to
the lower motor neurones of controls.
Next, in lower motor neurones from ALS cases, we
found that neurones with pathological loss of TDP43
from the nucleus, had lower levels of both 5mC and
5hmC, than in neurones with normal nuclear TDP43,
suggesting a relationship between TDP43 proteinopa-
thy and DNA methylation. It is worth noting that
approximately 90% of residual neurones retain nuclear
TDP43 in our cohort.
This pattern could imply either: (i) methylation is ini-
tially elevated in neurones in ALS but drops away
when TDP pathology develops or (ii) TDP43 pathology
favours neurones with lower methylation and leads to
death of neurones with lower levels of pathology, leav-
ing behind neurones with greater levels of methylation.
The direction of causation remains unknown. It is pos-
sible that: (i) ALS and TDP43 proteinopathy cause dys-
methylation; (ii) dysmethylation precipitates or
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GO:1903416 0.0064 response to glycoside
GO:0098657 0.0067 import into cell
GO:0042119 0.0067 neutrophil activation
GO:0030100 0.0074 regulation of endocytosis
GO:0000320 0.008 re-entry into mitotic cell cycle
GO:0016321 0.008 female meiosis chromosome segregation
GO:0045321 0.0081 leucocyte activation
GO:0031503 0.0086 protein-containing complex localization
GO:0002275 0.0089 myeloid cell activation involved in immune response
GO:0002444 0.0094 myeloid leucocyte-mediated immunity
GO:0097500 0.0096 receptor localization to nonmotile cilium
GO:0099505 0.0096 regulation of presynaptic membrane potential
GO:0022607 0.01 cellular component assembly
Hypomethylated
GO:0097274 0.0011 Urea homeostasis
GO:0071947 0.0027 Protein deubiquitination involved in ubiquitin-dependent protein catabolic process
GO:0023041 0.0037 Neuronal signal transduction
GO:0015867 0.0048 ATP transport
GO:0036444 0.0053 Calcium import into the mitochondrion
GO:0048681 0.0064 Negative regulation of axon regeneration
GO:0015865 0.0075 Purine nucleotide transport
GO:0022038 0.0085 Corpus callosum development
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facilitates ALS and TDP43 proteinopathy or (iii) a third
factor precipitates both dysmethylation and ALS/
TDP43 proteinopathy.
In contrast to the spinal cord, only minor intergroup
differences in neuronal methylation or hydroxymethy-
lation levels were found in motor or anterior frontal
cortex. One possible reason for this is that TDP43
pathology affects a lesser percentage of neurones in the
forebrain than in LMNs; another is the potential role of
selective vulnerability. In this context, it is interesting
that levels of neuronal DNA methylation and hydrox-
ymethylation were greater in the spinal cord than the
forebrain (motor and anterior frontal cortices): It is pos-
sible that lower motor neurones require higher methy-
lation levels for ongoing metabolism such that lower
levels increase the risk of degeneration, in the form of
TDP43 proteinopathy. Resolving the patterns of causa-
tion will require functional studies.
Previous studies have suggested that there may be
DNA methylation changes in ALS, but all have tended
to focus on tissue homogenates. Thus, Figueroa-
Romero et al. [32] conducted a study of DNA methyla-
tion on sporadic ALS spinal cord homogenates and
found an increase in DNA methylation using ELISA for
5mC and 5hmC. However, we (above) and others (see
introduction) have demonstrated cell-specific DNA
methylation changes. As ALS is characterized by neu-
ronal loss, astrogliosis and microgliosis [33], the rela-
tive proportion of different cells in ALS and control
tissue differ. Thus, any differences in overall methyla-
tion in homogenized tissue may reflect different cellular
populations more than different levels of methylation
within those cell types. This raises the possibility that
hypermethylation may be neuroprotective. This is an
enticing possibility as there are already pharmacologi-
cal agents that can reduce DNA methylation as well as
ongoing interest in developing agents to boost DNA
methylation [38]. Furthermore, DNA methylation is
heavily dependent on the so-called ‘one-carbon’ amino
acid metabolic pathway: This pathway is reliant on B
vitamins, obtained from dietary sources, and provides a
mechanism for the transfer of one-carbon groups
(which would be too volatile if not bound other co-fac-
tors) between molecules [39]. It is therefore relevant
that ALS is associated with elevated levels of homocys-
teine (a biomarker of B vitamin deficiency) and that B
vitamins can rescue a motor neurone cell model from
homocysteine-related toxicity [40].
A limitation of this study is that different glial cell
populations were pooled as opposed to not separated
into astrocytes, microglia and oligodendrocytes. It is
probable that there are differences in methylation in
these cell populations. It is also possible that these glial
types will have different methylation responses to ALS,
such that pooling the population will mask any patho-
logical changes that may exist.
Analyses using the MethylationEPIC platform were
performed in a subset of cases in an effort to elucidate
which biological processes may be most affected by
DNA methylation changes in ALS. Greater numbers of
methylated sites were observed in the residual lower
motor neurones of the C9ALS cohort than the control
cohort, reflecting finding of greater percentages of
5mC- and 5hmC- positive nuclei described above. The
sALS group had intermediate numbers of methylated
sites. With respect to individual genes, 402 gene pro-
moters were hypermethylated in ALS, and 330 were
hypomethylated in ALS. Gene ontology analysis of the
hypermethylated promoters in combined ALS heavily
implicated RNA metabolism with a particular emphasis
on RNA splicing. This correlates well with our previous
work using exon arrays on lower motor neurones
obtained by laser capture microdissection tissue from
post mortem material from the same brain bank [41]:
In this study, there was considerable evidence for aber-
rant mRNA splicing, as well as significant enrichment
of gene ontology terms among genes that were differen-
tially expressed. This study of mRNA expression also
provides some validation for the findings from DNA
methylation.
We have achieved a level of validation of the Methy-
lationEPIC platform results by demonstrating that the
genes that are differentially methylated in ALS are
involved in RNA processing (including splicing). How-
ever, one limitation of our study is that we have not
managed to establish a protocol for demonstrating cell-
and gene-specific differential methylation by means
other than the array analysis of bisulphite-converted
DNA.
The finding of aberrant methylation in spinal cord
lower motor neurones but not glia or forebrain neu-
rones contrasts with work on DNA damage and senes-
cence markers: There does not appear to be evidence of
DNA damage in lower motor neurones or forebrain
neurones although an excess of senescence markers is
seen in forebrain glia [15]. This raises the possibility
© 2020 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
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that different regions and cell types vary in which form
of DNA pathology develops in ALS.
Conclusion
We have studied methylation and hydroxymethylation
in brain and spinal cord using immunohistochemistry
for 5mC and 5hmC in sporadic and C9orf72-related
amyotrophic lateral sclerosis and controls (sALS and
C9ALS respectively). The residual lower motor neu-
rones of the spinal cord had higher levels of methyla-
tion and hydroxymethylation than the lower motor
neurones of controls. There was no difference between
sALS and C9ALS and no intergroup differences in glial
cell methylation. Furthermore, only small intergroup
differences (if any) were seen in the neurones of the
motor cortex and middle frontal gyrus. This suggests
that the most significant changes in DNA methylation
specifically affect lower motor neurones and not other
cell types or neurone types.
Within the two ALS groups, when lower motor neu-
rones with and without TDP pathology (loss of nuclear
TDP43) were compared, residual lower motor neurones
with TDP43 proteinopathy had lower levels of 5mC
and 5hmC than residual neurones with normal nuclei
that were positive for TDP43.
Thus, in the lower motor neurones, there are two
contrasting effects: ALS cases have higher levels of
methylation, whereas within ALS cases, the minority of
cells with TDP43 proteinopathy (nuclear loss) have
lower levels of methylation. This may suggest that ini-
tially, DNA methylation is elevated in ALS, but drops
away markedly when TDP43 pathology develops in a
cell. Alternatively, TDP43 pathology followed by cell
death affects cells with lower levels of DNA methylation,
such that more hypermethylated cells are left behind.
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